Skip to main content
Fig. 9 | Lipids in Health and Disease

Fig. 9

From: 4-cholesten-3-one decreases breast cancer cell viability and alters membrane raft-localized EGFR expression by reducing lipogenesis and enhancing LXR-dependent cholesterol transporters

Fig. 9

Comparison of the predicted binding mode for 4-cholesten-3-one with co-crystallized agonist 24(S),25-epoxycholesterol into the crystal structure of LXRβ ligand binding domain (pdb code 1P8D). 24(S),25-epoxycholesterol is represented by a stick model (yellow, carbon atoms; red, oxygen atoms; white, hydrogen atoms). Predicted binding of 4-cholesten-3-one is represented by a stick model (magenta, carbon atoms; red, oxygen atoms). Hydrogen bonding interactions for 24(S),25-epoxycholesterol with key residues in the LBD (His435 (protonated form) and Glu281) are indicated as yellow dotted line

Back to article page